Q3 2025 Halozyme Therapeutics Inc Earnings Call Transcript
Key Points
- Record royalty revenue of $236 million, a 52% increase year over year, driven by blockbuster subcutaneous therapies.
- Total revenue of $354 million, representing 22% growth year over year.
- Adjusted EBITDA growth of 35% over the prior year, showcasing the strength of the royalty-based business model.
- Successful expansion of ENHANZE technology, enabling more convenient subcutaneous delivery of treatments.
- Strategic acquisition of Elektrofi to enhance at-home administration of biologic therapies and expand drug delivery technology portfolio.
- Collaboration revenues decreased to $24 million from $48.4 million in the prior year period, primarily due to the timing of milestones achieved.
- Increased selling, general, and administrative expenses to $46.1 million, up from $41.2 million in the prior year period.
- Potential dilution from the Elektrofi acquisition, expected to be less than 5% dilutive to non-GAAP diluted EPS over the medium term.
- Uncertainty regarding the full impact of the Elektrofi acquisition on future financial performance.
- Challenges in maintaining growth momentum as key product contracts may terminate in the early 2030s.
Good afternoon. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's third-quarter 2025 financial and operating results conference call. (Operator Instructions) Please note this event is being recorded.
I will now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations and Corporate Communications. Please go ahead.
Thank you, Operator. Good afternoon and welcome to our third-quarter 2025 financial and operating results conference call. In addition to the press release issued today after the market closed, you could find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.
Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Nicole LaBrosse, our Chief Financial Officer, will review our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
